Thursday, March 28, 2024

Diadem Partners with Dementias Platform UK to Advance Diagnosis and Treatment of Alzheimer’s Disease

Diadem SpA, a company developing AlzoSure Predict, the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), announced that is has joined Dementias Platform UK (DPUK) as a corporate partner.

Also Read: MEDICALGORITHMICS Secured FDA Approval for Qpatch Wearable

DPUK is a public private partnership funded by the UK Medical Research Council to facilitate and accelerate the discovery of new ways to understand, diagnose, and treat dementia. It offers facilitated access to detailed information on more than three million individuals from 50 long-term health cohort studies. By assembling data from these studies, DPUK provides an integrated and collaborative environment, bringing together scientists from research institutions and industry to share knowledge and conduct joint research, while establishing new ways of working with academia, industry, regulators, health care providers, patients and the public.

“New tools such as Diadem’s prognostic blood test for Alzheimer’s disease that aim to identify high risk individuals early in the disease process are essential to efforts to dramatically improve the management of dementia,” said Vanessa Raymont, DPUK Associate Director. “We welcome Diadem as a DPUK corporate partner and look forward to working together to further investigate the utility of its AlzoSure Predict test to facilitate our efforts in dementia experimental medicine, and ultimately, to help improve the patient journey and patient outcomes.”

“We welcome the opportunity to join this unique network of research institutions and healthcare companies working together to transform the diagnosis and treatment of dementia,” said Paul Kinnon, Chief Executive Officer of Diadem. “Clinical studies confirm that our AlzoSure Predict blood test can accurately identify whether or not people with early signs of cognitive impairment will progress to Alzheimer’s disease up to six years before diagnosis, and it can distinguish the individual’s stage of decline. This makes it a potentially valuable tool for organizations conducting dementia research and developing new therapies. In turn, we expect to benefit from access to the exceptional patient databases and portals and related resources DPUK and its members have assembled, enabling us to further validate and extend the diagnostic utility of our proprietary biomarker technology.”

AlzoSure Predict is a non-invasive biomarker blood test that can identify with high accuracy whether individuals over the age of 50 with signs of cognitive impairment will or will not progress to Alzheimer’s dementia up to six years before diagnosis. Its utility is supported by clinical data from a large longitudinal study that was the basis for AlzoSure Predict’s recent CE-IVD marking in the E.U., and its Breakthrough Device designation from the U.S. Food & Drug Administration. The company’s technology uses an analytical method that includes a patented antibody developed by Diadem and designed to bind to U-p53AZ and its target sequences. U-p53AZ is a conformational variant of the p53 protein that has been implicated in the pathogenesis of AD in multiple studies.

Subscribe Now

    Hot Topics